NanoViricides is trading 10.69% up now at $1.16 after announcing its Phase II NV-387 oral-gummy trial for Ebola is scheduled to begin next week in the Democratic Republic of Congo.
- The announcement was made on September 15, 2026.
- The study will evaluate Bundibugyo ebolavirus treatment at an Ebola Treatment Center in Ituri province.
- The clinical-trial catalyst outweighs the broader biotech sector’s 2.11% decline; no volume data was provided.